Based on its current operating plan, Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of December 31, 2022, is sufficient to fund planned operating expenses and capital expenditure requirements into 2026.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Arvinas to Participate in Upcoming Investor Conferences
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- Arvinas price target lowered to $65 from $100 at Truist
- Arvinas pullback a buying opportunity, says Capital One
